Fetuin-A as A Marker of Vascular Calcification in Chronic Kidney Disease: Fetuin-A Marker of Vascular Calcification in Chronic Kidney Disease

Raisa Shaikh; Sama Ul Haque; Javed Mahmood; Imran Mehboob Baig; Ghazala Panhwar; Adeel Zafar

doi:10.54393/pjhs.v5i11.2198

Authors

Raisa Shaikh Department of Biochemistry, Shahida Islam Medical and Dental College, Lodhran, Pakistan
Sama Ul Haque Department of Anatomy, Fazaia Ruth Pfau Medical College, Karachi, Pakistan
Javed Mahmood Department of Pathology, Shahida Islam Medical and Dental College, Lodhran, Pakistan
Imran Mehboob Baig Department of Physiology, Shahida Islam Medical and Dental College, Lodhran, Pakistan
Ghazala Panhwar Department of Biochemistry, Shahida Islam Medical and Dental College, Lodhran, Pakistan
Adeel Zafar Department of Pathology, Shahida Islam Medical and Dental College, Lodhran, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i11.2198

Keywords:

Chronic Kidney Disease, Human Fetuin A, Vascular Calcifications, Association

Abstract

Multiple factors contribute to vascular calcification in chronic kidney disease. Fetuin-A is known for its potent inhibitory effects on ectopic calcification Objectives: To determine the association between fetuin-A levels and vascular calcification in chronic kidney disease patients. Methods: 90 samples were collected from patients admitted to the Nephrology ward of Shahida Islam Medical Complex, Lodhran due to renal disease, and 90 samples were collected from normal healthy subjects. Patients with congestive heart failure, use of hormonal contraceptives or hormone replacement therapy, malignancy, pregnancy and with a history of trauma or surgery within a month were excluded. Mann-Whitney was applied to test Serum Fetuin A between cases and controls keeping p<0.05 as statistically significant. Results: Of 90 cases and 90 controls, 63 male (70%) and 27 female (30%) were in cases and 45 (50%) male and female were in the control group. the cases exhibited lower levels of Fetuin-A (0.4416 ± 0.17 g/L) compared to the controls (0.752 ± 0.176 g/L). The clustering revealed a possible association between the severity of chronic kidney disease and decreased Fetuin-A levels. The values ranged from as low as 0.034 to a peak at 2.132 g/L, with several outliers distributed across the chronic kidney disease stage. Conclusions: It was concluded that comparing fetuin-A levels in chronic kidney disease patients to controls revealed a significant correlation. Patients had lower levels of fetuin-A compared to controls.

References

Francis A, Harhay MN, Ong A, Tummalapalli SL, Ortiz A, Fogo AB et al. Chronic Kidney Disease and the Global Public Health Agenda: An International Consensus. Nature Reviews Nephrology. 2024 Apr: 1-3. doi: 10.1038/s41581-024-00820-6.

El-Shishtawy S, Sherif N, Ibrahim A, Mamdouh S, Metwaly A, Abd Elazim IM. The Relation Between Fetuin-A and Inflammatory Markers in Cardiovascular Calcification in Hemodialysis Dependent Patient. African Journal of Biological Sciences. 2024 Jan; 20(1): 103-5. doi: 10.21608/AJBS.2024.286311.1089.

Werida RH, Abou-Madawy S, Abdelsalam M, Helmy MW. Omega 3 Fatty Acids Effect on the Vascular Calcification Biomarkers Fetuin a and Osteoprotegerin in Hemodialysis Patients. Clinical and Experimental Medicine. 2022 May: 1-0. doi: 10.1007/s10238-021-00740-w.

Roca-Tey R, Ramírez de Arellano M, González-Oliva JC, Roda A, Samon R, Ibrik O et al. Is Fetuin-A a Biomarker of Dialysis Access Dysfunction? The Journal of Vascular Access. 2023 May; 24(3): 458-64. doi: 10.1177/11297298211035846.

Nelson AJ, Raggi P, Wolf M, Gold AM, Chertow GM, Roe MT. Targeting Vascular Calcification in Chronic Kidney Disease. Basic to Translational Science. 2020 Apr; 5(4): 398-412. doi: 10.1016/j.jacbts.2020.02.002.

Ossareh S, Rayatnia M, Vahedi M, Jafari H, Zebarjadi M. Association of Serum Fetuin-A with Vascular Calcification in Hemodialysis Patients and Its' Impact on 3-year Mortality. Iran Journal of Kidney Disease. 2020 Dec; 14(6): 500-9.

Mohamed ON, Mohamed MR, Hassan IG, Alakkad AF, Othman A, Setouhi A et al. The Relationship of Fetuin-A with Coronary Calcification, Carotid Atherosclerosis, and Mortality Risk in Non-Dialysis Chronic Kidney Disease. Journal of Lipid and Atherosclerosis. 2024 May; 13(2): 194. doi: 10.12997/jla.2024.13.2.194.

Goodman WG. Calcium and Phosphorus Metabolism in Patients Who Have Chronic Kidney Disease. Medical Clinics. 2005 May; 89(3): 631-47. doi: 10.1016/j.mcna.2004.12.005.

Bostom A, Pasch A, Madsen T, Roberts MB, Franceschini N, Steubl D et al. Serum Calcification Propensity And Fetuin-A: Biomarkers of Cardiovascular Disease in Kidney Transplant Recipients. American Journal of Nephrology. 2018 Jul; 48(1): 21-31. doi: 10.1159/000491025.

Jirak P, Stechemesser L, Moré E, Franzen M, Topf A, Mirna M et al. Clinical Implications of Fetuin-A. Advances in Clinical Chemistry. 2019 Jan; 89: 79-130. doi: 10.1016/bs.acc.2018.12.003.

Pan X, Wen SW, Bestman PL, Kaminga AC, Acheampong K, Liu A. Fetuin-A in Metabolic Syndrome: A Systematic Review and Meta-Analysis. PloS One. 2020 Mar; 15(3): e0229776. doi: 10.1371/journal.pone.0229776.

Icer MA and Yıldıran H. Effects of Fetuin-A with Diverse Functions and Multiple Mechanisms on Human Health. Clinical Biochemistry. 2021 Feb; 88: 1-0. doi: 10.1016/j.clinbiochem.2020.11.004.

Kaur R and Singh R. Mechanistic Insights into CKD-MBD-Related Vascular Calcification and Its Clinical Implications. Life Sciences. 2022 Dec; 311: 121148. doi: 10.1016/j.lfs.2022.121148.

Zununi Vahed S, Mostafavi S, Hosseiniyan Khatibi SM, Shoja MM, Ardalan M. Vascular Calcification: An Important Understanding in Nephrology. Vascular Health and Risk Management. 2020 May; 16: 167-80. doi: 10.2147/VHRM.S242685.

Chekol Abebe E, Tilahun Muche Z, Behaile T/Mariam A, Mengie Ayele T, Mekonnen Agidew M, Teshome Azezew M et al. The Structure, Biosynthesis, and Biological Roles of Fetuin-A: A Review. Frontiers in Cell and Developmental Biology. 2022 Jul; 10: 945287. doi: 10.3389/fcell.2022.945287.

Kashani K, Rosner MH, Ostermann M. Creatinine: From Physiology to Clinical Application. European Journal of Internal Medicine. 2020 Feb; 72: 9-14. doi: 10.1016/j.ejim.2019.10.025.

Bargnoux AS, Kuster N, Cavalier E, Piéroni L, Souweine JS, Delanaye P et al. Serum Creatinine: Advantages and Pitfalls. Journal of Laboratory and Precision Medicine. 2018 Aug; 3. doi: 10.21037/jlpm.2018.08.01.

Smith ER. The Isolation and Quantitation of Fetuin-A-Containing Calciprotein Particles from Biological Fluids. Kidney Research: Experimental Protocols. 2016: 221-40. doi: 10.1007/978-1-4939-3353-2_15.

Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Sonmez A et al. Serum Fetuin-A Concentration and Endothelial Dysfunction in Chronic Kidney Disease. Nephron Clinical Practice. 2008 Mar; 108(3): c233-40. doi: 10.1159/000120209.

Makulska I, Szczepańska M, Drożdż D, Polak-Jonkisz D, Zwolińska D. The Importance of Fetuin-A in Vascular Calcification in Children with Chronic Kidney Disease. Advances in Clinical and Experimental Medicine. 2019; 28(4): 499-505. doi: 10.17219/acem/82517.

Cottone S, Nardi E, Mule G, Vadala A, Lorito MC, Riccobene R et al. Association Between Biomarkers of Inflammation and Left Ventricular Hypertrophy in Moderate Chronic Kidney Disease. Clinical Nephrology. 2007 Apr; 67(4): 209-16. doi: 10.5414/CNP67209.